THE ANTI-CD20 ANTIBODY RITUXIMAB REDUCES THE INFLAMMATORY AND PROTHROMBOTIC PROFILE OF LEUKOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS AND MODULATES THE ACTIVITY OF ENDOTHELIAL CELLS

Cecchi, I.Perez-Sanchez, C.Ruiz-Limon, P.de la Rosa, I. AriasAbalos-Aguilera, M. C.Jimenez-Gomez, Y.Ortega, R.Collantes-Estevez, E.Escudero, A.Barbarroja, N.Sciascia, S.Lopez-Pedrera, C.2025-01-072025-01-072017-06-010003-4967https://hdl.handle.net/10668/25555enTHE ANTI-CD20 ANTIBODY RITUXIMAB REDUCES THE INFLAMMATORY AND PROTHROMBOTIC PROFILE OF LEUKOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS AND MODULATES THE ACTIVITY OF ENDOTHELIAL CELLSconference outputopen access10.1136/annrheumdis-2017-eular.49161468-2060https://ard.bmj.com/content/annrheumdis/76/Suppl_2/497.1.full.pdf413181401448